In addition, MDS patients with SF3B1 mutations may also respond better to treatment with lenalidomide (LEN) compared to other high-risk mutations (e.g., ASXL1, U2AF1, TP53, etc.)(77). This evidence concerns the gene TP53 and myelodysplastic syndrome.